You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCiprofloxacin
Accession NumberDB00537  (APRD00424, EXPT00999)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A broad-spectrum antimicrobial carboxyfluoroquinoline. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acidNot AvailableNot Available
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acidNot AvailableNot Available
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acidNot AvailableNot Available
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acidNot AvailableNot Available
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acidNot AvailableNot Available
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acidNot AvailableNot Available
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acidNot AvailableNot Available
CiprofloxacinNot AvailableNot Available
CiprofloxacineNot AvailableNot Available
CiprofloxacinoNot AvailableNot Available
CiprofloxacinumNot AvailableNot Available
Salts
Name/CAS Structure Properties
Ciprofloxacin Hydrochloride
93107-08-5
Thumb
  • InChI Key: DIOIOSKKIYDRIQ-UHFFFAOYSA-N
  • Monoisotopic Mass: 367.109897401
  • Average Mass: 367.802
DBSALT000293
Brand names
NameCompany
BacquinorNot Available
BaycipNot Available
CifloxNot Available
CifloxinNot Available
CiloxanAlcon Canada
CiprinolNot Available
CiproNot Available
CiprobayNot Available
CiprocinolNot Available
CiprodarNot Available
CiproxanNot Available
CiproxinNot Available
FlociprinNot Available
ProquinNot Available
Proquin XRNot Available
Brand mixtures
Brand NameIngredients
Cipro HC Otic SuspensionCiprofloxacin hydrochloride + Hydrocortisone
CiprodexCiprofloxacin hydrochloride + Dexamethasone
CiproquinolCiprofloxacin hydrochloride + Hydrocortisone
Categories
CAS number85721-33-1
WeightAverage: 331.3415
Monoisotopic: 331.133219662
Chemical FormulaC17H18FN3O3
InChI KeyMYSWGUAQZAJSOK-UHFFFAOYSA-N
InChI
InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
IUPAC Name
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
SMILES
OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassHeterocyclic Compounds
ClassQuinolines and Derivatives
SubclassQuinoline Carboxylic Acids
Direct parentQuinoline Carboxylic Acids
Alternative parentsFluoroquinolones; Hydroquinolones; Hydroquinolines; Pyridinecarboxylic Acids; Fluorobenzenes; Aryl Fluorides; Diazinanes; Piperazines; Tertiary Amines; Enolates; Polyamines; Dialkylamines; Carboxylic Acids; Organofluorides
Substituentsdihydroquinolone; dihydroquinoline; pyridine carboxylic acid; pyridine carboxylic acid or derivative; fluorobenzene; 1,4-diazinane; aryl fluoride; benzene; aryl halide; piperazine; pyridine; tertiary amine; polyamine; secondary amine; carboxylic acid derivative; secondary aliphatic amine; enolate; carboxylic acid; organofluoride; organohalogen; organonitrogen compound; amine
Classification descriptionThis compound belongs to the quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at at least one position.
Pharmacology
IndicationFor the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure).
PharmacodynamicsCiprofloxacin is a broad-spectrum antiinfective agent of the fluoroquinolone class. Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. The mechanism of action of quinolones, including ciprofloxacin, is different from that of other antimicrobial agents such as beta-lactams, macrolides, tetracyclines, or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin. There is no known cross-resistance between ciprofloxacin and other classes of antimicrobials. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.
Mechanism of actionThe bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.
AbsorptionRapidly and well absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability is approximately 70% with no substantial loss by first pass metabolism.
Volume of distributionNot Available
Protein binding20 to 40%
Metabolism

Hepatic. Four metabolites have been identified in human urine which together account for approximately 15% of an oral dose. The metabolites have antimicrobial activity, but are less active than unchanged ciprofloxacin.

Route of eliminationApproximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug.
Half life4 hours
Clearance
  • Renal cl=300 mL/min
ToxicityThe major adverse effect seen with use of is gastrointestinal irritation, common with many antibiotics.
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption Not Available Not Available
Blood Brain Barrier Not Available Not Available
Caco-2 permeable Not Available Not Available
P-glycoprotein substrate Not Available Not Available
P-glycoprotein inhibitor I Not Available Not Available
P-glycoprotein inhibitor II Not Available Not Available
Renal organic cation transporter Not Available Not Available
CYP450 2C9 substrate Not Available Not Available
CYP450 2D6 substrate Not Available Not Available
CYP450 3A4 substrate Not Available Not Available
CYP450 1A2 substrate Not Available Not Available
CYP450 2C9 substrate Not Available Not Available
CYP450 2D6 substrate Not Available Not Available
CYP450 2C19 substrate Not Available Not Available
CYP450 3A4 substrate Not Available Not Available
CYP450 inhibitory promiscuity Not Available Not Available
Ames test Not Available Not Available
Carcinogenicity Not Available Not Available
Biodegradation Not Available Not Available
Rat acute toxicity Not Available Not applicable
hERG inhibition (predictor I) Not Available Not Available
hERG inhibition (predictor II) Not Available Not Available
Pharmacoeconomics
Manufacturers
  • Bayer healthcare pharmaceuticals inc
  • Bayer pharmaceuticals corp
  • App pharmaceuticals llc
  • Bedford laboratories
  • Claris lifesciences ltd
  • Hospira inc
  • Teva parenteral medicines inc
  • West ward pharmaceutical corp
  • Hikma farmaceutica (portugal) sa
  • Acs dobfar info sa
  • Baxter healthcare corp
  • Bedford laboratories div ben venue laboratories inc
  • Alcon inc
  • Akorn inc
  • Bausch and lomb pharmaceuticals inc
  • Fdc ltd
  • Hitech pharmacal corp
  • Nexus pharmaceuticals inc
  • Novex pharma
  • Pharmaforce inc
  • Wraser pharmaceuticals llc
  • Depomed inc
  • Apotex inc
  • Aurobindo pharma ltd
  • Barr laboratories inc
  • Carlsbad technology inc
  • Dr reddys laboratories ltd
  • Hikma pharmaceuticals
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Nostrum laboratories inc
  • Pliva inc
  • Ranbaxy pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa inc
  • Unique pharmaceutical laboratories
  • Watson laboratories inc
  • Allergan inc
Packagers
Dosage forms
FormRouteStrength
OintmentOphthalmic
SolutionIntravenous
SolutionOphthalmic
SuspensionOral
TabletOral
Tablet, extended releaseOral
Prices
Unit descriptionCostUnit
Cipro 400 mg Solution 40ml Vial259.99USDvial
Floxin Otic 0.3% Solution 10ml Bottle142.91USDbottle
Cipro 500 mg/5ml(10%) Suspension 100ml Bottle136.75USDbottle
Cipro HC 0.2-1% Suspension 10ml Bottle131.54USDbottle
Cipro 250 mg/5ml(5%) Suspension 100ml Bottle116.8USDbottle
Ocuflox 0.3% Solution 10ml Bottle106.09USDbottle
Ciprofloxacin HCl 0.3% Solution 10ml Bottle98.22USDbottle
Ciloxan 0.3% Ointment 3.5 gm Tube87.49USDtube
Floxin Otic 0.3% Solution 5ml Bottle86.49USDbottle
Ciloxan 0.3% Solution 5ml Bottle68.33USDbottle
Ocuflox 0.3% Solution 5ml Bottle57.32USDbottle
Ciprofloxacin HCl 0.3% Solution 5ml Bottle49.2USDbottle
ProQuin XR 3 500 mg 24 Hour tablet Disp Pack39.99USDdisp
Ciprofloxacin HCl 0.3% Solution 2.5ml Bottle26.03USDbottle
Ciloxan 0.3% eye drops13.33USDml
Ciprofloxacin 0.3% eye drop12.96USDml
Cipro hc otic suspension12.65USDml
Proquin xr 500 mg tablet12.18USDtablet
Cipro xr 1000 mg tablet11.91USDtablet
Ciprofloxacin-Ciproflox HCl 1000 mg 24 Hour tablet11.6USDtablet
Ocuflox 0.3% eye drops11.35USDml
ProQuin XR 500 mg 24 Hour tablet11.18USDtablet
Ciprofloxacin er 1000 mg tablet11.16USDtablet
Cipro XR 500 mg 24 Hour tablet10.88USDtablet
Cipro XR 1000 mg 24 Hour tablet10.75USDtablet
Cipro xr 500 mg tablet10.46USDtablet
Ciprofloxacin-Ciproflox HCl 500 mg 24 Hour tablet10.19USDtablet
Ciprofloxacin er 500 mg tablet9.8USDtablet
Floxin 400 mg tablet9.55USDtablet
Cetraxal 0.2% ear solution7.14USDeach
Floxin 200 mg tablet6.6USDtablet
Cipro 750 mg tablet6.26USDtablet
Cipro 500 mg tablet6.08USDtablet
Ciprofloxacin hcl 750 mg tablet5.65USDtablet
Floxin 300 mg tablet5.61USDtablet
Ciprofloxacin hcl 500 mg tablet5.59USDtablet
Cipro 250 mg tablet5.2USDtablet
Ciprofloxacin hcl 250 mg tablet4.59USDtablet
Floxin otic singles4.28USDeach
Ciprofloxacin hcl 100 mg tablet4.17USDtablet
Ciloxan 0.3 % Solution2.18USDml
Ciprofloxacin hcl powder1.29USDg
Apo-Ciproflox 0.3 % Solution1.18USDml
Pms-Ciprofloxacin 0.3 % Solution1.18USDml
Cipro i.v. 10 mg/ml vial0.72USDml
Cipro i.v. 200 mg/100 ml d5w0.16USDml
Ciprofloxacin 200 mg/20 ml vial0.13USDml
Ciprofloxacn-d5w 200 mg/100 ml0.03USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States77090222001-12-232021-12-23
United States52867541994-02-152011-02-15
Canada24142712005-09-272021-06-13
Canada13309461994-07-262011-07-26
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point255-257 °CNot Available
water solubility3E+004 mg/L (at 20 °C)NOWARA,A ET AL. (1997)
logP0.28TAKACS-NOVAK,K ET AL. (1992)
pKa6.09TORNIANEN,K ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility1.35ALOGPS
logP-0.57ALOGPS
logP-0.81ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)5.76ChemAxon
pKa (Strongest Basic)8.68ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.88 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity87.94 m3·mol-1ChemAxon
Polarizability33.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

DrugSyn.org

US4670444
General Reference
  1. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J: Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1986 Sep;30(3):444-6. Pubmed
  2. Hilliard JJ, Krause HM, Bernstein JI, Fernandez JA, Nguyen V, Ohemeng KA, Barrett JF: A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase. Adv Exp Med Biol. 1995;390:59-69. Pubmed
  3. Spivey JM, Cummings DM, Pierson NR: Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Pharmacotherapy. 1996 Mar-Apr;16(2):314-6. Pubmed
  4. Brouwers JR: Drug interactions with quinolone antibacterials. Drug Saf. 1992 Jul-Aug;7(4):268-81. Pubmed
External Links
ResourceLink
KEGG DrugD00186
KEGG CompoundC05349
PubChem Compound2764
PubChem Substance46504733
ChemSpider2662
BindingDB21690
ChEBI100241
ChEMBLCHEMBL8
Therapeutic Targets DatabaseDAP001360
PharmGKBPA449009
Drug Product Database2248439
RxListhttp://www.rxlist.com/cgi/generic/cipro.htm
Drugs.comhttp://www.drugs.com/cdi/ciprofloxacin-drops.html
PDRhealthhttp://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cip1082.shtml
WikipediaCiprofloxacin
ATC CodesS01AE03J01MA02S03AA07S02AA15
AHFS Codes
  • 08:12.18
  • 52:04.04
PDB EntriesNot Available
FDA labelshow(120 KB)
MSDSshow(73.9 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of acenocoumarol.
AluminiumFormation of non-absorbable complexes
AminophyllineCiprofloxacin may increase the effect of aminophylline.
AnisindioneThe quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of anisindione.
BendamustineDecreases metabolism, thus INCREASING levels of bendamustine. Decreased conversion of bendamustine to active metabolites. Concurrent administration of Ciproflaxacin or other CYP1A2 inhibitors may also increase the levels of bendamustine into active metabolites.
CaffeineCiprofloxacin may increase the effect and toxicity of caffeine.
CalciumFormation of non-absorbable complexes
Calcium AcetateCalcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
ClozapineCiprofloxacin may increase clozapine serum levels
CyclosporineCiprofloxacin may increase the effect and toxicity of cyclosporine.
DicoumarolThe quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of dicumarol.
DihydroxyaluminiumFormation of non-absorbable complexes
DuloxetineCiprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of duloxetine. Monitor for changes in the therapeutic and adverse effects of duloxetine if ciprofloxacin is initiated or discontinued.
DyphyllineCiprofloxacin may increase the effect of dyphylline.
EltrombopagAffects hepatic CYP1A2 metabolism, will increase effect/level of eltrombopag.
EthotoinDecreases the hydantoin effect
FoscarnetIncreased risk of convulsions
IronFormation of non-absorbable complexes
Iron DextranFormation of non-absorbable complexes
LomitapideThe effect of coadminstration of lomipatide with ciproflaxacin, and other moderate CYP3A4 inhibitors (such as aprepitant, amprenavir, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) is unknown. However, as coadministration is likely to increase serum concentrations of lomipatide, concomitant use is contraindicated.
MagnesiumFormation of non-absorbable complexes
Magnesium oxideFormation of non-absorbable complexes
MephenytoinDecreases the hydantoin effect
MethotrexateCiprofloxacine may decrease the metabolism of methotrexate. Monitor for changes adverse effects of methotrexate if ciprofloxacin is initiated.
OxtriphyllineCiprofloxacin may increase the effect of oxtriphylline.
PhenytoinCiprofloxacin may decrease the therapeutic effect of phenytoin.
ProcainamideCiprofloxacin may increase the effect of procainamide.
RamelteonCiprofloxacin increases levels/toxicity of ramelteon
RasagilineCiprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of rasagiline. Monitor for changes in the therapeutic and adverse effects of rasagiline if ciprofloxacin is initiated or discontinued.
RopiniroleCiprofloxacin may increase the effect and toxicity of ropinirole.
SevelamerSevelamer decreases ciprofloxacin bioavailability
SildenafilCiprofloxacin may increase the serum level of sildenafil.
SucralfateFormation of non-absorbable complexes
TacrineThe metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ciprofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ciprofloxacin is initiated, discontinued or if the dose is changed.
TheophyllineCiprofloxacin may increase the effect of theophylline.
ThiothixeneThe strong CYP1A2 inhibitor, Ciprofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ciprofloxacin is initiated, discontinued or dose changed.
TizanidineCiprofloxacin inhibits the metabolism and clearance of Tizanidine. Concomitant therapy is contraindicated.
WarfarinThe quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of warfarin.
ZincFormation of non-absorbable complexes
Food Interactions
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid milk, calcium containing dairy products, iron, magnesium, zinc, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take with a full glass of water.
  • Take without regard to meals.

Targets

1. DNA topoisomerase 4 subunit A

Kind: protein

Organism: Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
DNA topoisomerase 4 subunit A P43702 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chaudhry U, Ray K, Bala M, Saluja D: Mutation patterns in gyrA and parC genes of ciprofloxacin resistant isolates of Neisseria gonorrhoeae from India. Sex Transm Infect. 2002 Dec;78(6):440-4. Pubmed
  4. Lee JK, Lee YS, Park YK, Kim BS: Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea. Microbiol Immunol. 2005;49(7):647-53. Pubmed
  5. Leavis HL, Willems RJ, Top J, Bonten MJ: High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium. J Clin Microbiol. 2006 Mar;44(3):1059-64. Pubmed
  6. Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. Pubmed

2. DNA gyrase subunit A

Kind: protein

Organism: Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
DNA gyrase subunit A P43700 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chaudhry U, Ray K, Bala M, Saluja D: Mutation patterns in gyrA and parC genes of ciprofloxacin resistant isolates of Neisseria gonorrhoeae from India. Sex Transm Infect. 2002 Dec;78(6):440-4. Pubmed
  4. Abdelbaqi K, Menard A, Prouzet-Mauleon V, Bringaud F, Lehours P, Megraud F: Nucleotide sequence of the gyrA gene of Arcobacter species and characterization of human ciprofloxacin-resistant clinical isolates. FEMS Immunol Med Microbiol. 2007 Apr;49(3):337-45. Pubmed
  5. Taylor DE, Chau AS: Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates. Antimicrob Agents Chemother. 1997 Mar;41(3):665-71. Pubmed

3. DNA topoisomerase 2-alpha

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
DNA topoisomerase 2-alpha P11388 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N: Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother. 1992 Apr;36(4):751-6. Pubmed
  3. Hussy P, Maass G, Tummler B, Grosse F, Schomburg U: Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29(6):1073-8. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

3. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

4. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. Pubmed
  2. Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 08, 2013 14:22